Clinical Trial: Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Single Ascending Dose of ACC085 Injection in Healthy Chinese Adults

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07835633) titled 'Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Single Ascending Dose of ACC085 Injection in Healthy Chinese Adults' on Sept. 17.

Brief Summary: This trial is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) Phase I clinical trial conducted in healthy Chinese adults to evaluate the safety, tolerability and PK profiles of a single subcutaneous administration of ACC085 injection in healthy Chinese adults.

This is a single ascending dose study planned to enroll participants into 5 dose groups [94.4 mg (periumbilical abdomen), 314.8 mg (periumbilical abdomen), 944...